Type I Hypersensitivity Completed Phase 2 Trials for Benralizumab (DB12023)

Back to Type I Hypersensitivity

Also known as: Immediate Hypersensitivity / Hypersensitivity, Immediate / Immediate Type Hypersensitivity / Immediate hypersensitivity reaction / Immediate hypersensitivity reactions / Allergen-mediated IgE Allergy / Immediate hypersensitivity (disorder) / Hypersensitivity type I / Hypersensitivity type I NOS / Immunoglobulin E-mediated allergic disorder (disorder)

IndicationStatusPhase
DBCOND0030618 (Type I Hypersensitivity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03563066Effect of Benralizumab in Atopic DermatitisTreatment